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ABSTRACT 
Background: Nasal nitric oxide (nNO) is decreased in patients with primary ciliary dyskinesia (PCD) 
as compared to healthy subjects (HS). nNO measurement has been proposed as a screening tool for 
PCD, but NO analyzers are not widely available and reference values are lacking. 
Objectives: to determine the normal values of nNO in adults using a widely-used hand-held NO 
analyzer, and explore correlations with ambient NO, age, gender, weight, height, body mass index 
(BMI), and time of measurements. 
Methods: in a pilot phase, 25 adult HS had nNO sampled during breath hold (BH), tidal mouth 
breathing through a fixed resistance (straw, TB-S) and tidal breathing through a continuous positive 
airway pressure apparatus (TB-CPAP). TB-S was the most reproducible and comfortable sampling 
technique and was chosen to measure nNO in 200 adult HS of both genders aged 20 to 80 years, and in 
7 adults with PCD. 
Results: In HS, mean nNO adjusted for ambient NO was 517 ± 226 ppb and was negatively correlated 
with age (! = -3.76, p = 10-4). No correlation was found with gender, weight, height, BMI, month of the 
year, and time of the day.  The lower limit of normal nNO (2.5th centile) decreased from 201 ppb at age 
20 to 46 ppb at age 80. 6 out of 7 PCD patients had nNO below lower limit of normal. 
Conclusions: nNO values significantly decrease with age in adult HS. Reference values are available to 
use a handheld nNO analyzer as a screening tool for PCD in adults.  
 
 
Key words:  Kartagener syndrome, ciliary motility disorders, primary ciliary dyskinesia, nitric oxide, 
nose, healthy volunteers, adult
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INTRODUCTION 
Primary ciliary dyskinesia (PCD) is a rare autosomal recessive disorder characterized by dysfunction of 
motile cilia of the respiratory epithelium resulting in impaired mucociliary clearance. The main clinical 
manifestations of PCD are recurrent sinopulmonary infections leading to the development of 
bronchiectasis, and eventually chronic respiratory insufficiency. The diagnosis of PCD requires 
complex analyses of ciliary ultrastructure, beating frequency and pattern, and/or genetic studies, which 
are available in only a few specialised centers. For this reason, a simple screening tool is highly 
desirable. 
A significant decrease of nasal nitric oxide (nNO) has been observed in patients with PCD compared 
with healthy subjects (HS) (1–14) and several studies have suggested that nNO measurement could be 
used as a screening tool for PCD (1–4,6–13,15). However, several methods have been reported for nNO 
sampling and measurement, and no standardized protocol is currently available. Consequently, 
reference values for nNO are lacking, thus preventing to accurately identify patients with abnormally 
low nNO.  
The NIOX MINO is a hand-held NO analyzer, which is widely used by respiratory physicians to 
measure exhaled NO in asthmatics. By using a nasal adapter, the NIOX MINO can also be used to 
measure nNO. This device demonstrated a high reproducibility and a good correlation with other 
techniques (11,13,16–19) that are bulkier and more expensive. It could therefore be a screening tool for 
PCD. 
This study aimed at 5 objectives: 1) determine whether nNO can be reliably measured with the NIOX 
MINO, 2) identify the most reproductible and comfortable breathing technique to measure nNO, 3) 
explore possible correlations between nNO and ambient NO, age groups, gender, weight, height, body 
mass index (BMI), month of the year and time of the day, 4) determine normal nNO values in adult HS, 
5) compare nNO values in HS and patients with PCD. 
 
 
METHODS  
Subjects 
200 HS were recruited prospectively between December 2013 and October 2014 by word of mouth and 
through flyers distributed to the personnel of the Lausanne University Hospital. The subjects were 
stratified by gender and age to include 100 men and 100 women distributed equally into five 10-year 
age groups (20-30, 30-40, 40-50, 50-60, and > 60 years). Active smokers and subjects with the 
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following conditions were excluded: asthma, acute or chronic sinusitis, nasal polyps, sinus surgery, 
upper airway infection in the last 3 weeks, use of nasal corticosteroids in the last 3 weeks, nasal 
regurgitation during swallowing, cleft palate, uvulopharyngopalatoplasty, neuromuscular disorder, and 
chronic respiratory disease including cystic fibrosis and PCD. Patency of both nostrils and symmetrical 
motion of the soft palate were assessed before measurements. A group of 7 patients with PCD were 
also included for comparison with HS. All subjects gave written consent. The study was approved by 
the local Ethics Committee and recorded on ClinicalTrials.gov (Identifier NCT02133547).  
 
Material 
Nasal NO measurements were performed with the NIOX MINO analyzer (Aerocrine, Solna, Sweden), 
a hand-held device for measurement of exhaled NO, which can also be used to determine nNO. The 
analyzer is based on an electrochemical sensor technology. It covers a range of values between 5 and 
1700 parts per billion (ppb) and does not require calibration. To measure nNO, a disposable standard 
tubing is connected to the analyzer. This tubing is terminated by a nasal olive used to occlude the 
nostril. During sampling, ambient air is aspirated at a constant flow rate into one nostril, circulates 
around the posterior nasal septum, and enters through the other nostril into the sampling tubing then the 
analyzer. The aspiration flow rate may be set at 2 or 5 ml/sec, resulting in sampling times of 120 or 45 
seconds, respectively.  
 
Measurement of nNO 
An airflow rate between 0.25 l/min (4.2 ml/s) and 3 l/min (50 ml/s) has been recommended for nNO 
measurements (20). We used a rate of 5 ml/s, which has been used in previous studies (9,11,13). One 
methodological issue in nNO measurement is to avoid contamination of nasal air sample by exhaled 
alveolar air. Various techniques have been used previously for this purpose (9,11,13,14,21–23), and 
nNO appeared consistently low in PCD with all them (9,23). In a pilot phase of the present study, we 
compared 3 different breathing techniques for this purpose on the first recruited 25 subjects: 1) breath 
holding (BH), 2) tidal mouth breathing through a fixed resistance (straw) (TB-S), and 3) tidal breathing 
through a continuous positive airway pressure apparatus (TB-CPAP). Only the first 2 techniques have 
been previously described (9,11,13–15,21–23). For BH, the subject was asked to hold his breath during 
nNO sampling, i.e. 45 seconds. For TB-S, the subject was instructed to breathe spontaneously through 
the mouth with a straw in order to create a small positive pressure in the oropharynx and allow soft 
palate closure during exhalation. For TB-CPAP, the subject was asked to breathe spontaneously 
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through a mouthpiece connected to a continuous positive airway pressure apparatus set at a pressure of 
4 cm H2O. This technique aimed at providing soft palate closure throughout the whole respiratory 
cycle during quiet spontaneous breathing. Each subject performed 3 measurements of each of the 3 
methods, and was asked to rank each method from the most (3 points) to the less (1 point) comfortable.  
The method with the highest reproducibility and highest comfort score was chosen for determination of 
normal nNO values in total of 200 HS, including the 25 HS of the pilot phase. All measures were made 
in triplicates. Ambient NO was measured systematically. For comparison, nNO was also measured in 7 
patients with PCD. 
 
Statistics 
The nNO value of each subject was expressed as the average of 3 consecutive measures. Data are 
presented as mean ± standard deviation. Test-retest reliability was assessed with intraclass correlation 
coefficient (ICC). Linear regression was used to explore associations between nNO and respectively 
ambient NO, age, gender, weight, height, BMI, month of the year and time of the day. A p-value <0.05 
was considered significant. Calculations were performed with Stata. 
 
RESULTS 
Study population 
The study population consisted of 200 HS including 100 women and 100 men distributed equally into 
five age groups of 10 years (20-30, 30-40, 40-50, 50-60, > 60 years). The mean age was 44.3 years, the 
mean weight 71.0 kg, the mean height 169 cm, the mean BMI 24.7 kg/m2, and the mean ambient NO 
14 ppb. 7 adult HS aged 70 and over were included, the eldest was a 80 years old man. 17 subjects 
were excluded: 4 for asthma, 2 for chronic sinusitis, 6 for active smoking, 3 for nasal polyps and 2 for 
sinus surgery. A group of 7 patients with PCD were also included for comparison with HS. Their 
characteristics were: mean age 34.3 years, mean weight 65.6 kg, mean height 174 cm and mean BMI 
21.4 kg/m2. 
 
Choice of sampling method 
The results of the pilot phase used to determine the most reproducible and most confortable sampling 
method in 25 HS are shown in table 1. The intraclass correlation coefficient (ICC) was highest for TB-
S. The comfort score was also highest for TB-S. This method was thus chosen to determine normal 
values of nNO in the whole study population. 
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Determination of normal values of nNO 
The main average data are shown in table 2. The mean ambient NO was 14 ± 10 ppb. A significant 
correlation was observed between nNO and ambiant NO (! = 4.07, p = 0.013). To avoid any bias, 
ambient NO values were subtracted from the raw nNO values to obtain adjusted nNO values (nNOadj). 
After this substraction, the mean nNOadj in the study population was 517 ± 226 ppb. ICC between the 
three measurements was 0.85. 
By linear regression, age was significantly associated with nNOadj (! = -3.76, p = 10-4, r2 = 0.06). This 
means that for each increase in age of 1 year, nNOadj decreased of about 4 ppb. No significant 
correlation was found with gender (p = 0.47), weight (p = 0.16), height (p = 0.58), BMI (p = 0.05) and 
hour of the day (p = 0.46). Taking January as reference, no correlation was found between month of the 
year and nNOadj, except for May (! = -221, p = 0.03), but only 9 subjects were sampled during this 
month.  
As age was associated with nNOadj, normal values according to age were calculated by increments of 1 
year and expressed for the percentiles 2.5, 5, 25, 50, 75, 95 and 97.5 (table 3 and figure 1). The 2.5 and 
97.5 percentiles were considered as the lower and upper limits of normal, respectively. 
The values of nNOadj in adult HS were compared with those of patients with PCD. A markedly reduced 
nNOadj was observed in patients with PCD (figure 2). On average, nNOadj was 60 ± 54 ppb in this 
group. One 34 year-old female with PCD had a nNOadj value of 178 ppb, which was slightly above the 
lower limit of normal (percentile 2.5, 163 ppb), but still below percentile 5 (218 ppb). All other patients 
with PCD had nNO values below the lower limit of normal. 
 
 
DISCUSSION  
To our knowledge, this study is the first to determine normal values of nNO in adults, using a large 
cohort of HS of both genders and all age groups, and analyzing various parameters that can influence 
the values of nNO. We found that TB-S is the most reproducible and comfortable breathing techniques 
for nNO sampling. We demonstrated that nNO was significantly and negatively correlated with age, 
but was not influenced by weight, height, BMI and time of the day. These observations allowed us to 
establish normal values of nNO, using a widely available handheld analyzer. This study may broaden 
the use of nNO measurement as a screening technique for PCD and improve case finding in adults with 
bronchiectasis. 
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NO is a gas produced by three isoenzymes of NO synthase (NOS) via the oxidation of the amino acid 
L-arginine to L-citrulline in the presence of nicotinamide adenine dinucleotide phosphate, oxygen and 
others cofactors (24). Two of these isoenzymes (NOS1 and NOS3) are called constitutive NOS. They 
are active only when the concentration of calcium increases. The last one (NOS2) is called inducible 
NOS and is calcium-independent. All 3 isoenzymes are expressed in the respiratory epithelium. In the 
respiratory system, NO is involved in regulation of blood flow, mucus secretion, ciliary motion, platelet 
function, immunity and neurotransmission (25,26).  
 
A significant decrease of nNO has been observed in patients with PCD compared with HS (1–14). 
Several hypotheses have been proposed to explain the low nNO values in patients with PCD, including  
nNO ''trapping'' by viscous mucus, uptake by bacteria, or reduced expression or low activity of NOS 
isoenzymes (1,24,25). It has also been suggested that nNO is sequestrated in obstructed paranasal 
sinuses, or that its synthesis is reduced due to agenesis of paranasal sinuses (23,24,27). Hence, an 
important part of nNO comes from the paranasal sinuses. Baboons constitutively devoided of paranasal 
sinuses have extremely low nNO concentrations, while humans, rhesus monkeys and elephants, which 
possess paranasal sinuses, have much higher nNO concentrations. This suggests that paranasal sinuses 
are an anatomic requirement for nNO production (28). Aplasia or hypoplasia of frontal and/or 
sphenoidal sinuses is common in patients with PCD. One study showed that frontal and/or sphenoidal 
sinuses were either aplastic or hypoplastic on CT scans in 30 out of 41 (73%) patients with PCD (27). 
This could provide an explanation for low nNO in PCD, but requires further studies. 
 
Although most patients with PCD have low nNO values, several studies have also highlighted that 3 to 
7 % of patients with PCD have normal or even increased nNO concentrations (3,9,12,27). Indeed, one 
of our PCD patients has nNO values slightly above the lower limit of normal as defined in the present 
study by the 2.5 percentile. By providing normal values of nNO, our data will allow to study in more 
detail the sensitivity and specificity of nNO to detect patients with PCD. 
 
The main finding of the present study is that age was significantly and negatively correlated with nNO. 
For each increase in age of 1 year, nNOadj decreased of about 4 ppb. Two previous studies did not find 
any relationship between nNO and age (29,30). In the present study, gender, weight, height, BMI and 
time of the day were not correlated with nNO. Our findings are in agreement with previous studies, 
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which also did not find any association between gender and nNO (29–31). The effects of weight, height 
and BMI on the values of nNO have not been previously assessed. Regarding time of the day, a 
circadian effect on nNO was found in one study (32) but not in another one (30). No relationship was 
generally found in the present study between nNO and month of the year except for a reduction in May, 
when using January as an arbitrary reference. The significance of this finding is unclear at the present 
time. One can hypothesize that seasonal allergens may have influenced nNO measurements. However, 
NO being a mediator of inflammation, increased nNO values would have been expected in allergic 
rhinosinusitis. Furthermore, sinusitis was an exclusion criterion for this study. Also, the number of 
patients evaluated in May was small (n=9) and no attempts have been made to systematically stratify 
nNO measurements according to month of the year. Further studies are needed to clarify this issue.  
 
One limitation of this study is that, despite a rigorous measurement protocol, the nNO sampling 
conditions were not strictly controlled. Indeed, there was no certainty as to the complete closure of the 
soft palate during sampling time. Also, only one flow rate was tested (5 ml/s), mainly because of its 
shorter sampling time (45 sec as compared to 2 min at a flow of 2 ml/s). In the present study, nNO 
values were moderately but significantly associated with ambient NO. To remove this source of bias, 
and as recommended in several articles, ambient NO was subtracted from the raw values of nNO 
(15,20,31,33) to obtain adjusted nNO values truly reflecting nasal NO production. Another limitation is 
that our study was not designed to control for circadian and seasonal variations of nNO, and the 
possible effects of these parameters were only assessed retrospectively. Although no major effect has 
been observed, the occurrence of small effects could not be ruled out. 
 
Normal nNO values that we have determined for the NIOX MINO are certainly different from those 
measured with other devices, including those using chemiluminescence. Sampling of NO measured 
with the NIOX MINO differs significantly from conventional methods, as not the peak NO value, but 
the NO concentration of the total volume sampled is determined. In addition, the sampling period of a 
minimum of 45 seconds is much longer compared to conventional devices in which the maximum nNO 
level is usually reached after 10 to 20 seconds. In addition, only adults have been included in this study, 
and normal nNO values for children have not been determined. The reference values suggested in this 
article are therefore only valid for this particular analyzer and for adults. Also, the negative predictive 
value of a normal test is not precisely known, and should be studies in a large cohort of PCD. Despite 
these limitations, the NIOX MINO has the advantage of being portable and relatively inexpensive in 
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comparison to conventional stationary chemiluminescence analyzers. Additionally, it is already widely 
used in medical offices for the measurement of exhaled NO in patients with asthma. It can thus easily 
be adapted for measurement of nNO in these facilities. For these reasons, the NIOX MINO is an 
interesting screening tool for PCD. We believe that the present study can significantly broaden the use 
of nNO measurement to improve case finding in patients with suspicion of PCD, and thus prompt 
further diagnostic investigations. Further studies are needed to determine nNO values in a larger 
sample of adults with PCD, in children with PCD, as well as in patients with other causes of 
bronchiectasis. 
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Table 1: Intraclass correlation coefficient and comfort score in 3 methods of nNO sampling (n=25). 
  ICC Comfort score 
  mean 95% CI mean SD 
Breath hold (BH) 0.86 0.78-0.95 1.56 0.77 
Tidal breathing through straw (TB-S) 0.94 0.91-0.98 2.28 0.79 
Tidal breathing through continuous positive airway pressure 
apparatus (TB-CPAP) 
0.90 0.84-0.96 2.16 0.75 
ICC: intraclass correlation coefficient, CI: confidence interval, SD: standard deviation. 
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Table 2: nNO and ambient NO values in 200 adult HS expressed in parts per billion (ppb). 
 
 
 
 
 N mean SD median Interquartile range 
Raw nNO (average of 3 measurements) 200 531 228 518 300 
ambient NO 200 14 10 12 14 
nNO adjusted to ambient NO (average of 3 measurements) 200 517 226 498 296 
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Table 3: Normal values of nNO in adults according to age, expressed in ppb. 
Age (yr) q2.5 q5 q25 q50 q75 q95 q97.5 
20 201 257 441 582 734 977 1064 
21 198 254 438 578 730 973 1060 
22 195 251 435 575 726 969 1055 
23 193 248 432 571 723 965 1051 
24 190 246 428 568 719 960 1046 
25 187 243 425 564 715 956 1042 
26 184 240 422 561 711 952 1038 
27 182 237 419 557 708 948 1033 
30 174 229 409 547 697 935 1020 
31 171 226 406 544 693 931 1016 
32 168 223 403 540 689 927 1012 
33 166 220 400 537 686 923 1008 
34 163 218 397 534 682 919 1003 
35 160 215 394 530 678 915 999 
36 158 212 391 527 675 911 995 
37 155 209 388 524 671 907 991 
38 152 207 385 520 667 902 986 
39 150 204 381 517 664 898 982 
40 147 201 378 514 660 894 978 
41 144 198 375 510 656 890 974 
42 142 196 372 507 653 886 969 
43 139 193 369 504 649 882 965 
44 137 190 366 500 646 878 961 
45 134 188 363 497 642 874 957 
46 131 185 360 494 638 870 953 
47 129 182 357 490 635 866 948 
48 126 179 354 487 631 862 944 
49 124 177 351 484 628 858 940 
50 121 174 348 481 624 854 936 
51 118 171 345 477 621 850 932 
52 116 169 342 474 617 846 928 
53 113 166 339 471 614 842 924 
54 111 163 336 467 610 838 919 
55 108 161 333 464 607 834 915 
56 106 158 330 461 603 830 911 
57 103 155 327 458 600 826 907 
58 100 153 324 455 596 822 903 
59 98 150 321 451 593 818 899 
60 95 147 318 448 589 815 895 
61 93 145 315 445 586 811 891 
62 90 142 312 442 582 807 887 
63 88 140 309 439 579 803 883 
64 85 137 306 435 575 799 879 
65 83 134 303 432 572 795 875 
67 78 129 297 426 565 787 867 
69 73 124 292 419 558 780 859 
70 70 121 289 416 555 776 855 
71 68 119 286 413 551 772 851 
75 58 109 274 401 538 757 835 
76 55 106 271 398 534 753 831 
77 53 103 269 394 531 749 827 
80 46 96 260 385 521 738 815 
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Figure 1: Normal values of nNO according to age. 
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Figure 2: nNO values in adult HS (n=200) and patients with PCD (n=7). 
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